199 related articles for article (PubMed ID: 8661976)
21. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
22. Nasal calcitonin for treatment of established osteoporosis.
Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
[TBL] [Abstract][Full Text] [Related]
23. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
[TBL] [Abstract][Full Text] [Related]
24. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
26. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
Kapetanos G; Symeonides PP; Dimitriou C; Karakatsanis K; Potoupnis M
Acta Orthop Scand Suppl; 1997 Oct; 275():108-11. PubMed ID: 9385282
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
28. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
[TBL] [Abstract][Full Text] [Related]
29. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
31. Prevention of postmenopausal bone loss by rectal calcitonin.
Reginster JY; Jupsin I; Deroisy R; Biquet I; Franchimont N; Franchimont P
Calcif Tissue Int; 1995 Jun; 56(6):539-42. PubMed ID: 7648483
[TBL] [Abstract][Full Text] [Related]
32. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
[TBL] [Abstract][Full Text] [Related]
33. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
Gürlek A; Bayraktar M; Gedik O
Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
35. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
Overgaard K; Ravn P; Hansen MA; Christiansen C
Ugeskr Laeger; 1993 Aug; 155(31):2387-91. PubMed ID: 8346588
[TBL] [Abstract][Full Text] [Related]
36. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
37. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
38. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
39. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
[TBL] [Abstract][Full Text] [Related]
40. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
Kung AW; Yeung SS
J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
